We have developed highly potent synthetic activators of the vertebrate immune system that specifically target the RIG-I receptor. When introduced into mice, a family of short, triphosphorylated Stem Loop RNAs (SLRs) induces a potent interferon response and the activation of specific genes essential for antiviral defense. Using RNAseq, we provide the first in-vivo genome-wide view of the expression networks that are initiated upon RIG-I activation. We observe that SLRs specifically induce type I interferons, subsets of interferon-stimulated genes (ISGs), and cellular remodeling factors. By contrast, poly(I:C), which binds and activates multiple RNA sensors, induces type III interferons and several unique ISGs. The short length (10-14 base pairs) and robust function of SLRs in mice demonstrate that RIG-I forms active signaling complexes without oligomerizing on RNA. These findings demonstrate that SLRs are potent therapeutic and investigative tools for targeted modulation of the innate immune system. RIG-I is an innate immune sensor that plays a key role in recognizing and responding to infection by RNA viruses (1, 2). RIG-I is activated in conditions that introduce a terminal, double-stranded RNA molecule into the cell. These molecules can include viral genomes, replication intermediates, and any other species containing a stable RNA duplex that is terminated with a 5'-triphosphate or diphosphate group (3, 4) . RIG-I activation by RNA leads to the induction of type I interferon (IFN) genes through the activation of its adaptor molecule, MAVS (5). Another member of the RIG-I-like receptors (RLRs), MDA5, binds to long stretches of double-stranded RNA and similarly triggers type I IFN production through MAVS (6). Type I IFNs induce hundreds of genes, collectively known as IFN-stimulated genes (ISGs), which have a variety of antiviral effector functions (7, 8) . Both the RNA duplex and 5'-triphosphate moieties are important for specific, high affinity binding and signaling by RIG-I (9-11), and through a series of recent crystal structures and functional studies of RNA recognition by the RIG-I receptor, the molecular basis for these effects has been elucidated (3, 12) .
Introduction

Results
SLRs are an optimal design for RIG-I recognition
Unlike other RNA molecules that have been developed as RIG-I activators, complexes between SLRs and RIG-I molecules have been characterized crystallographically (3, 10, 23) , making it possible to visualize and optimize the molecular interaction networks that stabilize active RIG-I/RNA complexes. Relative to two-piece duplexes, the stemloop design provides simplicity, structural stability and resistance to nucleases, while presenting a single duplex terminus that fits precisely into the RNA binding pocket of RIG-I (Supp Fig. 1, 2) .
In order to examine the relative potency of SLRs and compare them with larger, more complex ligands, we employed a well-established cell-based reporter assay in which IFN induction is monitored upon transfection with RNA (22) . We tested the potency of two SLRs that vary in duplex length: SLR10 (containing 10 base pairs) and SLR14 (containing 14 base pairs). Recent studies indicate that RNAs bearing a diphosphate at the 5' terminus are bona fide ligands for RIG-I (33) . Thus, we compared the SLRs with a corresponding diphosphorylated stemloop (pp-SLR14), as well as stemloops lacking 5'-phosphate moieties (OH-SLR10 and OH-SLR14). We also included another control RNA, which is a 5'-triphosphorylated RNA that is the same length as SLR10, but is single-stranded and non structural (ppp-NS). In parallel, we examined the IFN response of a 19-base pair two-piece duplex that is commercially marketed as a RIG-I ligand (19mer dsRNA), and various other two-piece duplexes that have been utilized for previous structure/function studies ( Fig. 1A and Supp. Fig. 1 ). In addition, all of the duplexes are compared with poly(I:C), which is polydisperse and of unknown structure.
We observe that SLR10, SLR14 and pp-SLR14 are potent activators of RIG-I, inducing high levels of type I interferons (IFNs) in the cell-based assay (Fig. 1B) . Relative to the 14-base pair duplexes, SLR10 displays somewhat reduced activity, but this trend is not universal (vide infra). As expected, the IFN response requires both of the determinants that are required for RIG-I activation: a 5'-di or -triphosphate and a duplex RNA structure, as OH-SLR10, OH-SLR14 and ppp-NS ligands failed to stimulate a significant level of IFN induction (Fig. 1B) .
Notably, we failed to detect a significant IFN response with the RNA duplex (19mer dsRNA) that is being marketed and used as a specific RIG-I ligand (Supp. Fig. 1) (32, (34) (35) (36) . We observed a small response from two RNA duplexes that have been utilized as RIG-I ligands in previous studies (9) (21mer dsRNA, 23mer dsRNA), and a moderate response from a double-stranded RNA that we specifically designed to have a high thermodynamic stability relative to previously published duplex designs (24mer dsRNA) (Fig. 1B) . The IFN responses of the dsRNA ligands track closely with their relative thermodynamic stability (Supp Fig. 1) , establishing that the efficacy of RIG-I ligands depends on a stable terminal duplex structure, which is enforced by the stemloop design in the SLRs. In keeping with previous findings, we observe a strong response from poly(I:C) ( Fig. 1B) . Taken together, these findings confirm previous work demonstrating the potency of SLRs in cell culture (10, 37, 38) , and benchmark SLR potency relative to other putative RIG-I ligands.
SLRs stimulate a potent IFN response in animals
In order to examine the ability of SLRs to induce type I IFN responses in vivo, we used a well established RNA delivery method to introduce RNA ligands intravenously in living mice (17) . Wild type C57BL/6 mice were injected intravenously (IV) with RNA ligands complexed to polyethylenimine (PEI), and five hours later, IFN-α in mouse sera was measured by ELISA. A dose/response study of SLR10 showed an optimal response at 25 µg of RNA (Supp. Fig. 3 ). An RNA stemloop lacking a 5'-triphosphate (OH-SLR10) failed to induce IFN-α at any concentration (Supp. Fig. 3 ).
We then examined the IFN-α response to SLR10 molecules that were either synthesized (synth SLR10) or transcribed in vitro (trans SLR10) at the optimal RNA dose. We observed elevated levels of IFN-α after injection of synthetic SLR10 compared to transcribed SLR10 (Figure 2A ). These results indicated that chemically synthesized SLR10, likely due to the enrichment in complete product, is more potent than transcribed RNA. Therefore, from here on, we exclusively use SLRs and dsRNA that are synthesized in house.
We examined the extent of the IFN response induced by the various RNA ligands. Systemic IFN-α response was robustly induced by SLR10 and SLR14 (Figure 2A ). In contrast, no induction of IFN-α was observed after OH-SLR10 or ppp-NS injection in vivo. The widely utilized ligand poly(I:C) induced IFN-α, but to a considerably lower degree (Figure 2A ), thereby providing a benchmark for the relative in vivo activity of the SLR10 and SLR14 ligands.
Next, we analyzed the time course of IFN-α and TNF-α secretion in response to in vivo injected SLR10. By 2 hours post IV injection, SLR10 elicited robust IFN-α and TNF-α responses ( Figure 2B , C). By 5 hours post injection, SLR10 sustained higher levels of IFN-α, which dropped off by 10 hours post-injection and were undetectable after 24 hours. In contrast, TNF-α levels peaked at 2 hours and were undetectable by 10 hours post-injection. These data indicate that SLRs induce rapid, robust and transient levels of IFN-α and TNF-α response in mice.
Diphosphorylated stemloop RNAs are also potent inducers of type I IFN in vivo
To evaluate the ability of diphosphorylated RNA to trigger IFN responses in vivo, we injected 25 µg of pp-SLR10, OH-SLR10 or SLR10 into mice as described above, collecting the spleen after 5 hours of induction, and measuring the IFN-α mRNA by RT-qPCR. Both pp-SLR10 and SLR10 induced comparable levels of IFN-α mRNA in the spleen ( Figure 3A ). As expected, the non-phosphorylated OH-SLR10 induced minimal levels of IFN-α mRNA. In a separate experiment, we observed comparable ability of pp-SLR14 and SLR14 to induce IFN-α expression in the spleen ( Figure 3B ). Consistent with our in vitro ( Figure 1 ) and in vivo analyses ( Figure 2 ), both ppp-SLRs and pp-SLRs induced more robust IFN-α mRNA than poly(I:C) ( Figure 3B ). These results indicate that both in the serum (IFN-α protein; Figure 2 ) and spleen (IFN-α mRNA; Figure 3B ), SLR and pp-SLR induce robust and comparable IFN-α expression.
Type I IFN induction by SLRs is RIG-I specific
Based on structural work and biochemical data (12) , SLRs were designed to be a ligand that is specific for RIG-I, as other PRRs recognize nucleic acids with different types of features, such as extended length (MDA-5), or single-stranded character (TLR7). However, it was important to test the comparative PRR specificity of SLR ligands using a diversified set of experiments. Using the IFN-β promoter-luciferase reporter system described above, we found that both SLR10 and pp-SLR10 activate the IFN-β promoter when RIG-I is expressed, but not when MDA5 is expressed ( Figure 1C ). By contrast, poly(I:C) induced IFN-β promoter activation in both RIG-I and MDA5expressing reporter cells, consistent with the fact that poly(I:C) contains recognition determinants important for both types of receptors (duplex termini and long RNA duplex regions).
To evaluate RIG-I specificity, we used siRNAs to knock down RIG-I expression in A549 lung epithelial cells. We then challenged the cells with SLRs and evaluated effects on IFN-β expression ( Fig. 4A ). Because knockdown of RIG-I was efficient in these experiments, it was possible to sensitively monitor the influence of challenge ligands on gene expression. Unlike their stimulatory behavior in WT cells, SLRs failed to induce IFN-β in the RIG-I KD cells (Fig. 4A ). In addition, RIG-I KD resulted in diminished expression of ISGs, including Rsad2 (viperin), and Mx1 (Fig. 4A) .These experiments show that SLRs are specifically and functionally recognized by RIG-I in human cells.
To examine RIG-I specificity in a living animal, and to evaluate the potential contribution of other RNA sensors and signaling adaptors during IFN induction by SLRs, we introduced 25 µg of SLR10 i.v. into WT, Tlr7 -/-, Mavs -/or Mda5 -/mice. We were unable to examine the RIG-I deficient mice due to embryonic lethality (39) . We collected sera at 5 hours and IFN-α levels were assessed by ELISA. These results demonstrate that MAVS, but not TLR7 or MDA5, is critical for IFN-α secretion following SLR injection ( Figure 4B ). The fact that SLRs require MAVS, but not MDA5, for IFN-α induction (Fig.  4B ), and the fact that RIG-I knockdown eliminates this response in human cells ( Fig.  4A ) indicates that RIG-I is the receptor for IFN induction by SLRs.
Specific activation of RIG-I by SLR and poly(I:C) reveals a distinct pattern of gene expression
Given the potential for SLR and other RNA agonists for clinical applications, it was of interest to determine the global gene expression profiles following injection of SLRs and other activating RNA ligands. In particular, it was important to explore the landscape of expressed genes in an unbiased manner so that we might be able to identify new processes involved in RIG-I induction. We therefore carried out RNAseq analysis of expressed genes in the mouse spleen 3 hours after injection of 25 µg of SLRs or poly(I:C). To our knowledge, this is the first time that the profile of RNA-induced gene expression has ever been determined in an animal.
Broadly speaking, we observe that SLR14 and SLR10, showed similar gene expression profiles (Supp. Fig. 4 ). To a first approximation, we can therefore use SLR14 as a proxy for short, multiphosphorylated RNA duplex ligands and compare them with RNAs that elicit a different profile of expressed genes, such as poly(I:C). We first measured the differentially expressed genes (DEGs) of SLR14 relative to vehicle, and compared that with the DEGs of poly(I:C) relative to vehicle. By comparing the profiles, we can assess the relative impact of poly(I:C) and SLR14 on patterns of gene expression.
Both SLR14 and poly(I:C) induced a shared set of genes involved in antiviral response and innate immunity, including Ifit2, Oas3, Csf1, Tlr2, Tlr9, Nod2 and Ddx58 (RIG-I) (Supp. Figure 4 and Supp. table 1). In addition, genes involved in T cell activation and effector functions (Cd86, Tnf, Ifng, Il1b, Gzmb) were elevated in response to both SLR14 and poly(I:C) (Supp . Table 1 ). Both SLR14 and poly(I:C) induced a marked downregulation in the expression of genes that belong in a variety of biological pathways, suggesting a shared pathway for co-opting basal cellular function upon induction. Many of these genes encode membrane proteins that are associated with processes such as ion transport, formation of cell junctions, and Wnt signaling (Supp. Figure 4 and Supp. Table 1 ). In addition, many myeloid expressed C-type lectins are downregulated, possibly indicating the loss of dendritic cell subsets from the spleen.
In contrast, the two types of ligands have differential effects on other gene families ( Fig. 5 an SUPP. Table 2 ). A striking divide in the gene expression pattern was seen for type I vs. type III IFNs by SLRs and poly(I:C) respectively ( Fig. 5C ). Type III IFNs, IFN-λ2 and IFN-λ3, were more highly expressed upon introduction of poly(I:C) ( Fig. 5C ). In the mouse, the IFN-λ1 gene is a pseudogene. In addition, matrix metalloproteinases MMP8 and MMP9 ( Fig. 5D and SUPP.table 2), which degrade extracellular matrix for cell migration and wound repair, are upregulated to a greater extent by poly(I:C). Similarly, SEMA4F, PLAGL1 and TYRO3 were more upregulated by poly(I:C) injection than SLRs ( Fig. 5B and D) . Conversely, type I IFNs (10 IFN-α genes and IFN-β) were all elevated by injection of SLRs compared to poly(I:C) ( Fig. 5C ). In addition to type I IFNs, TNFSF4 (OX40L) and several other genes with known roles in immune function (SATB2, VAV3, and VDR) were more strongly upregulated by SLR14 ( Fig. 5 and SUPP. Table 2 ) (40) (41) (42) . A divergent noncoding transcript (9130024F11Rik) that shares a promoter with SATB2 is also highly upregulated (SUPP. Table 2 ). This suggests a shared mechanism of transcriptional regulation and supports our observations of SATB2 regulation, but the function of these noncoding divergent transcripts is poorly defined.
The two treatments also showed differential effects on downregulated genes, including a Rag1/2 repressor (Zfp608) that was preferentially downregulated by SLR14 and two repressors of T-cell maturation that were preferentially downregulated by poly (I:C) (Lax1 and Dtx1) (Supp. Table 2 ) (43) (44) (45) . Taken together, these data indicate that SLR14 and related ligands elicit a potent, type I IFN dominant innate immune response while poly(I:C) induces a stronger type III IFN response. Although we have focused on global trends among groups of known genes, the RNAseq data is a rich source of information about potentially novel pathways involved in RNA and antiviral response.
To compare the effects of SLR14 relative to those of triphosphorylated, singlestranded RNA, we examined the DEGs of ppp-NS relative to vehicle, again comparing the response to that of SLR14 (Supp. Figure 4 ). DEG responses for ppp-NS and SLR14 showed little overlap, confirming that RIG-I is not activated by triphosphate moieties on single-stranded RNA molecules. Taken together, it is now possible to map a network of gene regulatory pathways that are selectively modulated by RIG-I, and which will be activated upon induction of specific RIG-I ligands, such as synthetic, multiphosphorylated duplexes and viral panhandle RNAs.
Discussion
RIG-I is a cytosolic sensor that has evolved to detect the presence of RNA molecules that have invaded or been inappropriately expressed within vertebrate cells. Upon binding and responding to these RNA molecules, RIG-I initiates a signaling cascade that leads to pro-inflammatory responses and ultimately apoptosis. In this way, RIG-I plays a key role in the successful innate immune response to viruses, and its activation is being increasingly linked to antitumor response.
Given the antiviral effects of RIG-I, and its potential utility in cancer treatment, it is vital to understand the mechanism of its activation and the molecular structure of its targets, particularly as they are presented in a living animal. This will lead to a better understanding of natural pathways for RIG-I induction, and it will confer the ability to activate and repress RIG-I at will with synthetic RNA molecules and other agonists, giving rise to powerful new therapeutic strategies. Understanding the molecular determinants of RIG-I recognition will also guide the improvement of other therapeutic RNA strategies that elicit unwanted activation of RIG-I, such as siRNA and antisense RNA treatments. We therefore set out to identify a potent, minimal ligand for specific RIG-I induction in animals. Building on crystallographic, biochemical, and cell biological data, we created a set of stable, multiphosphorylated RNA duplexes (the SLRs), and performed comparative testing of their influence on IFN induction and overall gene expression in vitro and in vivo. By testing these molecules in knockout and knockdown contexts, we have shown that short (>10 bp), stable RNA duplexes bearing a 5'triphosphate or diphosphate are potent and specific activators of RIG-I.
The potency of the SLR ligands is significant because biophysical and cell biological experiments from multiple labs has demonstrated that short, polyphosphorylated synthetic RNA duplexes, ranging in length from 10-24 base pairs, can productively bind RIG-I and induce robust RIG-I signaling in cell culture (3, 9, 10, 22, 24, 26) . These findings challenged the notion that RIG-I forms functional aggregates on RNA, suggesting that RIG-I/MAVS oligomerization is mediated by other features, such as ubiquitination of the CARD domains (28) (29) (30) . However, until now, the immune responses and gene expression programs induced by small polyphosphorylated RNA ligands had not been assessed in vivo, leaving open the possibility that a functional RIG-I response in an animal requires larger RNA molecules.
Here, we establish that polyphosphorylated RNA stemloops as short as ten base-pairs can induce a potent IFN response by RIG-I in vivo. This is significant because SLR10 and SLR14 can only bind a single RIG-I molecule, establishing that RIG-I can perform its function without multimerizing on RNA, and validating the in vivo activity of short dsRNA. Our findings establish that RIG-I activation can be achieved with stable, synthetic RNA agonists that are chemically well-defined and structurally characterized, which is important for development as a therapeutic. The stemloop design is ideal because it permits RIG-I binding at only a single position on the RNA molecule (the polyphosphate terminus), while the stabilizing UUCG tetraloop enforces a duplex conformation that is resistant to nucleases and strand dissociation. The SLRs therefore represent a powerful new set of tools for exploring the physical basis of RIG-I signaling and for harnessing the therapeutic potential of this process.
The identification of SLR agonists provides a unique opportunity to explore the gene expression pathways that are specifically controlled by RIG-I, and to differentiate them from networks that are initiated by other types of receptors. This has not been possible in the past because RNAs used in previous studies of RIG-I response (such as poly(I:C) or Sendai virus RNA) have large, complex structures that are capable of recruiting many types of receptors (such as MDA5, TLR3 and TLR7), and binding a host of potential coactivator proteins. Furthermore, the majority of studies of RIG-I induction have been conducted in cell culture systems, and there is a lack of transcriptome-wide analysis of RIG-I induction in living animals. We therefore utilized the SLRs as tools to examine gene expression upon RIG-I activation in vivo, and to compare the SLRs with other types of RNA molecules.
As expected, SLRs and poly(I:C) both induce a large number of genes that are associated with antiviral immunity and ISGs. However, SLRs selectively induced elevated levels of genes belonging to type I IFNs, whereas poly(I:C) induced higher levels of type III IFN genes (IFN-λ2 and IFN-λ3) . While the precise mechanisms by which a given RIG-I agonist triggers type I vs. type III IFN genes is unknown, recent studies highlight that the intracellular location of MAVS might dictate these differential gene activation pathways. Kagan and colleagues have shown that MAVS residing in the peroxisomes preferentially induce type III IFN expression, while MAVS residing on the surface of mitochondria activate the transcription of type I IFN (46) . Both of these pathways require IRF3 to induce the IFN genes, but the type III pathway depends on IRF1, while the type I pathway depends on Erk1. Therefore, it is conceivable that MAVS activation is preferentially induced at the mitochondria by SLRs, and at the peroxisome by poly(I:C). An alternative hypothesis is that SLRs trigger a specific cell type that preferentially induces type I IFNs, while poly(I:C) stimulates another cell type that selectively induces type III IFNs. Future studies are needed to distinguish these possibilities by analyzing the cell types responsible for the secretion of respective IFNs in vivo. Whatever the mechanism might be, our comprehensive transcriptome results have important implications for the use of RNA ligands in humans. For instance, type I IFNs play a key role in initiating anti-tumor CD8 T cell responses (47) (48) (49) . Thus, SLRs are expected to better elicit type I IFNs during cancer immunotherapy. On the other hand, systemic recombinant IFN-α therapy using conventional methods is not well tolerated due to significant side effects, so it may be prudent to minimize the type I response, particularly for localized pathologies. For example, hepatocytes express IFN-λR during the antiviral response against HCV and might benefit from a type III IFN response (50, 51) . Thus, poly(I:C) may be a more effective therapy for HCV given its preferential induction of type III IFNs.
Our RNAseq analysis revealed RIG-I induction of unexpected gene families, including several without annotated immune functions, suggesting potentially novel pathways involved in RIG-I response. For example, genes involved in pH homeostasis (Car4 and Sct) were selectively upregulated by SLR14. Local acidosis has long been associated with inflammation, and these genes may be indicative of a pathway that functions as a response to this environment (52) (53) (54) . Furthermore, the maintenance of pH homeostasis could benefit an immune response to tumors with acidic microenvironemnts. Three other genes preferentially upregulated by SLR14 have been primarily characterized as neuronal proteins (Gje1, Cbln1, and Itpr1). Further investigation of these neuronal proteins revealed homology with known effectors of immune function (connexins, complement domains, and inositol receptors, respectively), which may suggest a bone fide role for these genes in the immune response (55) (56) (57) (58) .
RIG-I induction and antiviral responses are expected to cause restructuring of cellular structure and metabolism, and it is therefore intriguing that specific sets of gene families are downregulated upon systemic RIG-I activation in the animal. For example, membrane proteins are significantly downregulated upon stimulation. In particular, genes involved in cell-cell contacts are downregulated, which is consistent with the migration of cells out of the spleen to peripheral tissues upon immune activation. Furthermore, C-type lectins are downregulated, including many expressed on dendritic, macrophage, and NK cells, suggesting a depletion of these cells in the spleen as they migrate to peripheral tissues (59, 60) .
In summary, we have demonstrated that SLRs are highly potent activators of the IFN response in living animals. They provide valuable tools for exploring the molecular determinants of RIG-I activation in the complex environment of the mammalian immune system and they facilitate characterization of the gene expression pathways that are controlled by the RIG-I receptor. Given their small size and chemically-defined composition, SLRs also represent a promising new class of oligonucleotide therapeutics with potential applicability as antivirals, vaccine adjuvants and antitumor agents.
Materials and Methods
RNA synthesis and purification: All triphosphorylated RNA oligonucleotides were synthesized on a MerMade 12 DNA-RNA synthesizer (BioAutomation), using previously described synthetic procedure (61, 62) . The 2'-pivaloyloxymethyl phosphoramidites were obtained from ChemGenes. Synthesized triphosphorylated RNAs were deprotected with ammonium hydroxide as described (62) and purified by polyacrylamide gel electrophoresis. RNA molecules were further analyzed for purity by mass spectrometry (Novatia LLC). Low molecular weight poly(I:C) was purchased from Invivogen and used without further purification.
HEK 293T Cell Culture and IFN-β Induction Assays:
Cell based experiments were conducted in HEK 293T cells because they do not express endogenous RLRs (proteinatlas.org). Cells were grown and maintained in 15 cm dishes containing Dulbecco's Modified Eagle Medium (DMEM; Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum and Non-Essential Amino Acids (Life Technologies). IFN-β induction assays were conducted in 24-well format. Briefly, 0.5 mL of cells at 100,000 cells/mL were seeded in each well of tissue culture treated 24-well plates. After 24 hours, each well of cells was transfected with 3 ng of pUNO-hRIG-I or pUNO-hMDA5 (Invivogen), 6 ng pRL-TK constitutive Renilla luciferase reporter plasmid (Promega), and 150 ng of an IFN-β/Firefly Luciferase reporter plasmid using the Lipofectamine 2000 transfection reagent (Life Technologies) per the manufacturer's protocol. Protein expression was allowed to proceed for 24 hours, at which point the cells were challenged by transfection of 1 µg of the indicated RNA or LMW polyI:C (6 wells per RNA condition), also using the Lipofectamine 2000 reagent. After 12 hours, cells were harvested for luminescence analysis. These experiments were performed in biological triplicate.
Induction of the IFN-β promoter was analyzed using a dual luciferase assay. After aspiration of the growth media, 100 µL of passive lysis buffer (Promega) was added to each well, and incubated for 15 min at room temperature. The lysed cells were transferred to a 96-well PCR plate and clarified by centrifugation. Next, 20 µL samples of the supernatant were transferred to a 96-well assay plate for analysis using the Dual-Luciferase Reporter Assay System (Promega). Luminescence was measured using a Biotek Synergy H1 plate reader. The resulting Firefly luciferase activity (i.e. the induction of IFN-β) was normalized to the activity of the constitutively expressed Renilla luciferase to account for differences in confluency, viability and transfection efficiency across sample wells.
Mice: C57BL/6NCrl (WT) mice were purchased from Charles River Laboratories (Frederick, MD). Tlr7 (The Jackson Laboratory; B6.129S1-Tlr7tm1Flv/J) and Mavs knockout mice (The Jackson Laboratory; B6;129-Mavstm1Zjc/J) were backcrossed to C57BL/6 mice for several generations. Mda5 knockout mice (The Jackson Laboratory; B6.Cg-Ifih1tm1.1Cln/J) were a kind gift from Dr. Erol Fikrig. All animal procedures were performed in compliance with Yale Institutional Animal Care and Use Committee protocols.
In vivo injection of SLRs:
SLRs were complexed to in vivo-jetPEI® (Polyplus transfection) according to manufacturer's instructions, with N/P ratio = 8. Unless otherwise indicated, 25 µg of RNA in a 200 µl volume was injection per mouse intravenously. At various time points, sera were collect and ELISA (PBL Assay Science, eBioscience) was performed according to manufacturers instructions. Spleens were collected into RNAlater (QIAGEN) for RNA extraction. A minimum of 3 mice per group was used per experiment.
RNA extraction from spleen:
Tissues collected into RNAlater were blotted dry and transferred into Trizol (Thermo Fisher Scientific) in a Lysing Matrix D tube (MP Biomedical) for homogenization. Supernatant was collected for chloroform phase separation and RNA was precipitated using isopropyl alcohol. The RNA pellet was then washed with 75% ethanol and redissolved in water.
Quantification of gene expression in animals by qRT-PCR:
cDNA was synthesized from RNA using iScript cDNA synthesis kit (Bio-Rad). Quantitative PCR was performed using iTaq Universal SYBR Green (Bio-Rad) on a CFX Connect instrument (Bio-Rad). Ifna-4 (F: CTG CTA CTT GGA ATG CAA CTC; R: CAG TCT TGC CAG CAA GTT GG) and Mx1 (F: TGT ACC CCA GCA AAA CAT CA; R: TTG GAA GCG CTA AAG TGG AA) expression was normalized to Hprt (F; GTT GGA TAC AGG CCA GAC TTT GTT G; R: GAG GGT AGG CTG GCC TAT TGG CT).
RIG-I knockdown experiments:
A549 cells (ATCC, Manassas, Va., CCL-185) were propagated in F-12K Medium (Kaighn's Modification of Ham's F-12 Medium) containing 10% fetal bovine serum (FBS). Cells were reverse transfected in a 24-well plate with a RIG-I (DDX58)-specific siRNA sequence (GE Healthcare Dharmacon Inc Cat# D-012511-01-005) at a final concentration of 25 nM RNA and 0.5 µl lipofectamine 2000 (Thermo Fisher Scientific) per well, according to the manufacturer's instructions. After 4h incubation at 37 °C, transfection medium was replaced with fresh growth medium and incubated for another 20h at 37 °C. Following siRNA treatment, cells were challenged with either mock (transfection reagent only) or 1.7 ng/µl exogenous purified RNA (SLR14 or SLR10) and 0.5 µl of Lipofectamine2000 reagent (Thermo Fisher Scientific) per well, according to the manufacturer's instructions. Cells were transfected for 6h at 37°C, then trypsinized, washed in phosphate-buffered saline (PBS), and pelleted for total RNA extraction.
Total RNA from cells was extracted using the RNAeasy Mini Kit (Qiagen, Valencia, CA, USA) protocol. Genomic DNA contamination was removed by DNAseI treatment (Qiagen) directly on the Mini kit column. Total RNA was reverse transcribed into cDNA using oligo dT primers and Superscript III reverse-transcriptase enzyme (Thermo Bioinformatic Analysis Sequenced reads were checked for quality control using the FastQC tool (Babraham Bioinformatics, Babraham Institute, Cambridge, UK. Good quality reads were mapped to the reference genome (GRCm38/mm10) using the software package Tophat v 2.0.6 (63) . Default settings were used, except for the mean inner mate distance between the pairs that was set to 150bp. A maximum of two mismatches and a minimum length of 36 bp per segment were allowed. The BAM files from Tophat were then converted to SAM format by Samtools (v 1.4) (64) and raw counts estimated by the Python script HTSeq count (65) . Reference GTF file for gene annotation was downloaded from iGenomes website (http://cufflinks.cbcb.umd.edu/igenomes.html).
We generated approximately 628 million paired-end sequencing reads by multiplexing 24 samples on 4 lanes of Illumina NextSeq500 platform. On average, each sample achieved a sequencing depth of 26 million paired-end reads. The overall mapping rate against the reference transcriptome up to 92%. Normalized gene expression levels, represented as counts per million (CPM), were calculated for 39,169 transcripts from the Ensembl database and were processed for statistical analysis with EdgeR (66) .
The resulting raw counts per gene were processed by the EdgeR program to perform normalization, clustering and estimate differential expression. EdgeR (Bioconductor release 3.4.2) performs differential abundance analysis using a pair-wise design based on negative binomial model, as an alternative to the Poisson estimates. Normalization of the sequenced libraries was performed to remove effects due to differences in library size. The resulting p-values were corrected for multiple testing using the Benjamini-Hochberg false discovery rate (FDR) approach.
We identified genes uniquely regulated by SLR14 or poly(I:C) using a two-step filtration process. First, each treatment was compared to vehicle and differentially expressed genes were selected that had p-values <0.05 and >2-fold change in expression level. This subset of genes was then compared between the SLR14 and poly(I:C) treatments. Genes that were differentially expressed between SLR14 and poly(I:C) with p-values <0.05 and >2-fold change in expression level were deemed "significantly more up/downregulated by a specific treatment". All other genes were deemed "mutually up/downregulated". Mutually up/downregulated genes were Reduction of RIG-I expression resulted in reduced IFN and ISG production. Mice lacking TLR7, MAVS, and MDA5 were injected i.v. with SLR10 and 5 hours later, sera were collected to measure IFNα. Asterisks indicate significant difference from WT mouse control (***P < 0.0005) (B).
Figure 5. Distinct splenic gene expression between mice treated with SLRs and poly(I:C).
Mice were injected i.v. with SLRs or poly(I:C) and 3 hours later, RNA from spleens was purified for RNASeq. Heatmaps were generated for genes preferentially regulated by treatment with SLR (A) or poly(I:C) (B). The heatmaps include all genes that are differentially expressed between SLR14 and poly(I:C) (> 2 fold-change and FDR < 0.05). Highly statistically significant genes (FDR < 1x10 -5 ) are labeled. Type I and type III interferons are preferentially expressed following stimulation with SLR and poly(I:C), respectively (C). Several additional genes, with and without reported immune functions, were differentially induced by SLRs or poly(I:C) (FDR < 1x10 -5 ) (D). were synthesized as described in Methods. The dsRNAs used in this experiment vary in length and stability, and were tested to facilitate comparisons with published studies on annealed duplexes as RIG-I ligands. The 24mer dsRNA duplex (43.9 kcal/mol stability) has a terminal sequence analogous to SLR10 and SLR14, and approximately twice the duplex length. The 19mer dsRNA duplex (32.7 kcal/mol) is the same sequence and reported composition as an RNA that is marketed as a RIG-I ligand (Invivogen), but it was synthesized in-house, in parallel with all other RNAs used in this study. The 21mer dsRNA (35.9 kcal/mol) & 23mer dsRNA (37.4 kcal/mol) duplexes are identical in sequence and reported composition to those reported previously in studies of RIG-I activation (9) . Importantly, these have a variable 3'-overhang on the nontriphosphorylated duplex end. Free energies of all duplexes, including overhanging ends, were calculated as described (68). 
5'ppp-GAAGCAAUCUCCACUUACUAGAAA-OH3'
